The 2025-2030 World Outlook for MRSA Drugs - Image 1

Out of stock

This item is currently unavailable

The 2025-2030 World Outlook for MRSA Drugs

Subjects

Out of stock

Price data last checked 13 day(s) ago - will refresh soon

View at Amazon

One email. No newsletter. No nudges.

Out of stock for 13 days. The last 3 returns each lasted under a day — get on the list.

Out of stock 13 days · usually back within 14 days

NEW HERE?

Amazon shows you one price. We show you all of them.

Tosheroon watches Amazon prices so you don't have to. Every product on Amazon has a price history — we make it visible. Set the price you'd actually pay, and we'll email you the second it gets there. No app, no account, one email.

WHAT'S ON THIS PAGE

↓ Price chart
when this has been cheap or pricey

↓ Forecast
where the price is heading next

↓ Statistics
all-time high & low, recent range

↑ Price alert
name your number, we'll email you

Price History & Forecast

Grey patches = out of stock. Cheaper = lower on the chart. Hover for exact prices.

No price data yet

Price history will appear here once data is collected from Amazon.

Price Distribution

No price data available for histogram

Description

This study covers the world outlook for MRSA drugs across more than 190 countries. For each year reported, estimates are given for the latent demand, or potential industry earnings (P.I.E.), for the country in question (in millions of U.S. dollars), the percent share the country is of the region, and of the globe. These comparative benchmarks allow the reader to quickly gauge a country vis-à-vis others. Using econometric models which project fundamental economic dynamics within each country and across countries, latent demand estimates are created. This report does not discuss the specific players in the market serving the latent demand, nor specific details at the product level. The study also does not consider short-term cyclicalities that might affect realized sales. The study, therefore, is strategic in nature, taking an aggregate and long-run view, irrespective of the players or products involved. In this report we define the sales of MRSA drugs as including all commonly understood products and/or services falling within this broad category, irrespective of product packaging, formulation, size, or form. Companies participating in this industry include Absynth Biologics, Allergan, AmpliPhi Biosciences, AstraZeneca, Basilea Pharmaceutica, Baxter International, Cempra, CrystalGenomics, Debiopharm Group, Galapagos, GlaxoSmithKline, Innovation Pharmaceuticals, KYORIN Pharmaceutical Company, Lytix Biopharma, Melinta Therapeutics, Merck & Company, Nabriva Therapeutics US, NovaDigm Therapeutics, Paratek Pharmaceuticals, Pfizer, R-Pharm-US, Savara, Sealife PHARMA, Sequella, The Medicines Company, and XBiotech. In addition to the sources indicated, additional information available to the public via news and/or press releases published by players in the industry was considered in defining and calibrating this category. All figures are in a common currency (U.S. dollars, millions) and are not adjusted for inflation (i.e., they are current values). Exchange rates used to convert to U.S. dollars are averages for the year in question. Future exchange rates are assumed to be constant in the future at the current level (the average of the year of this publication's release in 2024).

Product Specifications

Format: paperback
ASIN: B0CZ2FDRDH
Category: Books > Subjects
Domain: Amazon UK
Release Date: 03 March 2024
Listed Since: 30 April 2024

The 2025-2030 World Outlook for MRSA Drugs

Out of stock for 13 days. The last 3 returns each lasted under a day — get on the list.

Price History & Forecast

Price Distribution

Description

Product Specifications

Similar Products You Might Like

The 2023-2028 Outlook for MRSA Drugs in the United States

The 2023-2028 Outlook for MRSA Drugs in China

The 2023-2028 Outlook for MRSA Drugs in India

The 2023-2028 Outlook for MRSA Drugs in Japan

The 2025-2030 World Outlook for Lipopeptide MRSA Drugs

The 2023-2028 Outlook for MRSA Drugs for US Zip Codes

The 2023-2028 Outlook for Lipopeptide MRSA Drugs in China

The 2023-2028 Outlook for Lipopeptide MRSA Drugs in India

The 2023-2028 Outlook for Lipopeptide MRSA Drugs in Japan

The 2023-2028 Outlook for Lipopeptide MRSA Drugs in the United States

The 2023-2028 Outlook for Lipopeptide MRSA Drugs for US Zip Codes

Humana MRSA Protocols: Cutting-Edge Technologies 2069 Book

The 2025-2030 World Outlook for Antibiotic Resistance

The 2025-2030 World Outlook for Smart Antimicrobials

The 2023-2028 Outlook for Anti-Malarial Drugs in India

The 2023-2028 Outlook for Anti-Malarial Drugs in the United States

The 2021-2026 World Outlook for Smart Antimicrobials

The 2026-2031 World Outlook for Antibiotic Resistance

The 2026-2031 World Outlook for Macrolide Antibiotics

The 2025-2030 World Outlook for Anti-Malarial Drugs

The 2025-2030 World Outlook for Gram-Positive Bacterial Infections

Antimicrobial Resistance in Clinical Practice: Evidence-Based Treatment Pathways for MDR Gram- Negative and Complex Hospital Infections

The 2016-2021 Outlook for Systemic Antibiotic-Sulfonamide Combination Pharmaceuticals in the United States

The 2023-2028 Outlook for Anti-Malarial Drugs in China